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ABSTRACT
Objective To investigate whether the 1998 government
policy for mandatory fortification of flour and pasta
products with folate was followed by a reduction in the
prevalence of severe congenital heart defects.
Design Time trend analysis.
Setting Province of Quebec, Canada.
Participants Infants born in 1990-2005 identified with
severe congenital heart defects (tetralogy of Fallot,
endocardial cushion defects, univentricular hearts,
truncus arteriosus, or transposition complexes) in
Quebec administrative databases.
Methods Data analysed in two time periods (before and
afterfortification).Birthprevalencemeasuredannuallyas
infants (live and stillbirths) with severe congenital heart
defects per 1000 births in Quebec. Changes in the birth
prevalence from the period before to the period after
fortification were estimated with Poisson regression.
Results Among the 1324440 births in Quebec in 1990-
2005therewere2083infantsbornwithseverecongenital
heart defects, corresponding to an average birth
prevalence of 1.57/1000 births. Time trend analysis
showed no change in the birth prevalence of severe birth
defects in the nine years before fortification (rate ratio
1.01, 95% confidence interval 0.99 to 1.03), while in the
seven years after fortification there was a significant 6%
decrease per year (0.94, 0.90 to 0.97).
ConclusionsPublichealthmeasurestoincreasefolicacid
intakewerefollowedbyadecreaseinthebirthprevalence
ofseverecongenitalheartdefects.Thesefindingssupport
the hypothesis that folic acid has a preventive effect on
heart defects.
INTRODUCTION
Folic acid intake around the time of conception
reduces the risk of neural tube defects in the
newborn.
1-3 Measures to increase intake of folic acid
in this period include multivitamin supplementation
4
and fortification of grain products such as flour and
pasta.
56 While supplements tend to target only
women planning a pregnancy, fortification measures
are larger in scope and target all women of childbear-
ing age. Fortification of grain products with folic acid
has been mandatory in the Unites States since January
1998
6 and in Canada since December 1998
5 and was
followed within months by significant increases in the
concentrations of erythrocyte folate among women of
childbearing age
7-10 and a decrease in the birth preva-
lence of neural tube defects.
3791112
Recent evidence suggests that folic acid might also
decrease the birth prevalence of congenital heart
defects,
13-20 the most common of all birth defects.
2122
The existing evidence for an association between
folic acid and congenital heart defects, however, is still
inconclusive.
20 In 2007, a statement from the Ameri-
can Heart Association Council emphasised the impor-
tance of this possible association and the need for
corroborative evidence from population based
studies.
20
We assessed, on a population level, the impact of
folic acid fortification policies on the birth prevalence
of severe congenital heart defects in Quebec, Canada.
METHODS
Data sources
Weidentifiedinfantsbornwithseverecongenitalheart
defects in Quebec from 1990 to 2005 using provincial
administrative databases that record all contacts
between Quebec residents and the medical system
since 1983. We used three administrative databases
and specific selection algorithms to capture live births
andstillbirths.Toidentifyliveinfantsbornwithsevere
congenitalheartdefects,weuseddiagnosticandproce-
dural codes for severe congenital heart defects
recordedin the physicians’ claimsdatabaseof Quebec
or the hospital discharge summary database of Que-
bec, or both.
23 Infants with severe congenital heart
defects who die immediately after birth might not be
captured in these databases because there is a waiting
time of up to several weeks until the infant is issued a
permanent Medicare number. Furthermore, the wait-
ing time for being issued a permanent Medicare num-
ber has decreased over time. Consequently, to avoid a
possible detection bias in time trends, we decided to
rely solely on the Quebec death registry to identify
infant deaths due to severe congenital heart defects.
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infantdeathscausedbyseverecongenitalheartdefects
becausethelawrequiresthatallsuddenorunexpected
deathsininfantsbesubjecttoautopsyandthatthephy-
sicianorcoroner,orboth,providedetailedevidenceof
death. The death registry also records the cause of
death for stillbirths, defined as delivery of a fetus of
500 g or more that died before birth.
24 This process
did not change during the study period. Therefore,
we also included in our analyses stillbirths caused by
severe congenital heart defects. All three administra-
tive databases use diagnostic codes that conform to
ICD-9 (international classification of diseases, ninth
revision),exceptforthedeathregistry,whichswitched
to the 10th revision in 2000.
In accordance with received ethical approval, the
anonymity of patients was preserved. Specifically,
patients were identified in the physicians’ claims and
hospital discharge summary databases using
scrambled Medicare numbers as a unique identifier,
while data on infant deaths and stillbirths were deliv-
ered to us in the form of annual and monthly statistics
rounded to a multiple of five. Information on the
annual number of live births in Quebec for 1990-
2005 was retrieved from Statistics Canada reports.
25
Study population
Thestudypopulationincludesallbirths(livebirthsand
stillbirths)inQuebecfrom1990to2005ofinfantswith
severe congenital heart defects identified from admin-
istrativedatabaseswithcompletepopulationcoverage.
The term “severe congenital heart defects” included
tetralogy of Fallot, endocardial cushion defects, uni-
ventricular hearts, truncus arteriosus, and transposi-
tion complexes. Table 1 presents the diagnostic and
procedural codes used to identify severe congenital
heart defects in the three databases. Patients with
severe congenital heart defects were further grouped
intothosewithorwithoutconotruncaldefects,defined
as teratology of Fallot, truncus arteriosus,and transpo-
sition complexes.
Whilepreviousstudieshavesuggestedthatfolicacid
might also have a protective effect on non-severe
congenital heart defects,
2026 we restricted our analyses
to severe defects because detection of mild lesions
could be affected by ascertainment bias. Indeed, the
detection of mild lesions has increased over time
because of the availability of non-invasive detection
methods such as cardiac ultrasonography.
23 On the
other hand, severe congenital heart defects have early
clinical manifestations that require further investiga-
tions, both invasive (cardiac catheterisation) and non-
invasive (cardiac ultrasonography), and therefore are
not likely to be affected by ascertainment bias.
Case definition
We identified live births in the physicians’ claims and
hospitalisation databases and included them in the
study if they had diagnostic code or procedural code
for a congenital heart defect billed in the first three
years of life, and they also had a code for severe con-
genitalheartdefectsatanytimeduringfollow-upinthe
database. The diagnostic codes in the physicians’
claims database were considered valid if billed by a
cardiologistoracardiovascularsurgeon,whilethepro-
cedural codes were considered valid if billed by a
cardiovascular surgeon.
23 Patients who had at least
one valid billing for a severe conotruncal defect were
classified as having a conotruncal defect; otherwise
they were classified as having a non-conotruncal
defect.
We identified infant deaths and stillbirths due to
severe congenital heart defects in the death registry
and included them in the study if a diagnosis code for
severe congenital heart defects was recorded as the
main cause of death on the death certificate. If the
main cause of death was a conotruncal defect, the
infant was classified accordingly.
Study design
We performed a time trend analysis to estimate the
change in birth prevalence of severe congenital heart
defects before and after the implementation of manda-
toryfolicacidfortificationofgrainproductsinCanada
in 1998.
Folate fortification and study periods
The 16 year period covered by this study, 1990-2005,
covers the time of all major folic acid interventions
implemented in Canada for the prevention of neural
tube defects. The first folic acid measure, in 1993, was
a policy paper by the Society of Obstetricians and
Gynecologists of Canada that recommendedthat phy-
sicians advise women planning a pregnancy to take
daily multivitamin supplements including 0.4-1.0 mg
offolicacid.
4Yetmanywomeneitherdonotplantheir
pregnancies or do not take multivitamin supplements
when planning a pregnancy.
2728 These women can,
however, be targeted indirectly by increasing the folic
acid content of basic food products such as flour and
pasta. Consequently, the US and Canadian govern-
ments amended their legislations in March 1996 and
November 1996, respectively, to require the
Table 1 |Case definitions of severe congenital heart disease
by diagnostic codes and surgical procedure codes, or both
Diagnosis
Diagnostic codes Surgical
procedures codes‡ ICD-9* ICD-10†
Endocardial cushion
defect
7456 Q212 Atrioventricular
canal repair
Tetralogy of Fallot 7452 Q213, Q201 Fallot repair
Univentricularhearts 7453,
7467
Q204, Q234 Fontan procedure
Transposition
complex
7451 Q203, Q205 Atrial/arterial switch
Truncus arteriosus 7450 Q200 —
*Billed by cardiologist, cardiovascular surgeon in physician’s claims
database, during hospital admission in database, or recorded as main
cause of death on death certificate in death registry database.
†Recorded as main cause of death on death certificate in death registry
database.
‡Billed by cardiovascular surgeon in physician’s claims database.
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pasta products, and each government offered the
industry two years to comply with the new policy.
56
Theeffective deadlinesforimplementation were Janu-
ary 1998 in the US and December 1998 in Canada.
56
Reportsfromtheindustry
10suggestthatfortificationin
the US was largely completed within 15 months of the
announcement of the new policy. The target daily
intake with the fortification policy was significantly
lower than that with multivitamin supplementation
(up to 1 mg/day) because higher intakes might mask
vitamin B-12 deficiency in older people.
9
For the purposes of our time series analyses we
divided the study period into two periods, before and
after fortification. The cut off between the two periods
in Canada was set at 1 January 1999, after we applied
two lag times: a 15 month lag time between the
announcement of the policy and its implementation
and a nine month lag time between conception, when
exposuretofolicacidislikelytohaveanimpactonthe
heart formation,
29-31 and birth. Although the 15 month
lag time between announcement of the policy and its
implementation was reported in the US,
10 we consid-
eredthatitisreasonabletoassumeasimilarlagtimein
Canada.Indeed,thefolicacidpolicyinCanadaclosely
followedtheoneintheUS,andthetwocountriesshare
a competitive market, supporting this assumption.
Similarly,ourchoiceofaninemonthlagtimebetween
conception and birth is based on existing evidence
from Quebec that suggests that over 87% of deliveries
in Quebec were at term during the study period.
32 The
period before fortification therefore covered the nine
yearperiodfrom1January1990to31December1998,
while the period after fortification covered the seven
yearperiodfrom1January1999to31December2005.
Statistical analysis
Thebirthprevalenceofseverecongenitalheartdefects
wasdeterminedannuallyasthenumberofinfants(live
birthsandstillbirths)bornwithseverecongenitalheart
defects per 1000 births in Quebec. Descriptive ana-
lyses include reports of the average birth prevalence
over the whole study period and in the periods before
andafterfortification.Giventhattheaveragebirthpre-
valence over a longer period of time can mask signifi-
cant secular trends in that period, we conducted time
seriesanalysesthatfocusontheobservedandexpected
time trends in the two periods. Specifically, we esti-
mated the observed time trends in the period before
and after fortification in a Poisson regression model
withtheannualbirthprevalenceasthedependentvari-
able and the calendar year (birth year) as the indepen-
dentvariable.Weestimatedtheexpectedtimetrendin
the period after fortification by applying the estimates
from the Poisson model in the period before fortifica-
tion to the calendar years from the period after fortifi-
cation. From these analyses we report rate ratios and
95% confidence intervals, where the rate ratios repre-
sent the annual change in birth prevalence of severe
congenital heart defects in the two periods. Finally,
we tested whether the change in time trend from the
first period to the second was significant by adding to
thePoissonmodelaninteractiontermbetweenthebin-
ary variable “period” (before/after fortification) and
the calendar time variable. The interaction was inter-
pretedasasignificantchangeinthetimetrendfromthe
period before to the period after fortification if the P
value of the interaction term was below 0.05. The ana-
lyseswererepeatedforconotruncalandnon-conotrun-
cal defects. Analyses were performed with SAS
statistical software (version 8.02, Cary, NC).
Follow-up period
To extend our follow-up period, we included infants
born in 2005. Because most infants born with severe
congenital heart defects are identified in the first year
of life, however, some infants born in 2005 might have
been missed, depending on the month of birth. We
therefore corrected the birth prevalence in year 2005
using an adjustment procedure that is based on the age
specific detection rates for congenital heart defects from
the birth cohorts with a complete three year follow-up.
The adjustment method involved three steps. Firstly,
we used the observed births in years with complete data
to estimate the probability of an infant being identified
with congenital heart defects in the database before
each age, measured in months, from the first month of
life to the 12th month of life. Secondly, we sorted the
observed number of infants born in 2005 by age (in
months) on 31 December 2005. Finally, we divided the
agespecificnumberofobservedbirthsfromstep2bythe
age specific probabilities from step 1 to estimate the total
number of observed and unobserved births. The adjust-
mentprocedureshowedthatweneededtoadd11infants
to 2005, which increased the birth prevalence in 2005
from 0.94/1000 births before adjustment to 1.08/1000
births after adjustment.
Todeterminewhetheranydecreaseinobservedpre-
valence remained significant we also performed a sen-
sitivity analysis in which we excluded 2005, which
required the adjustment as described above.
RESULTS
Birth prevalence of severe congenital heart defects
During the study period there were 1324440 births in
Quebec and 2083 infants born with severe congenital
heartdefects,correspondingtoanaveragebirthpreva-
lenceof1.57/1000births.Theannualbirthprevalence
of severe congenital heart defects ranged from 1.08 to
1.81 cases per 1000 births (interquartile range 1.41-
1.74). The averagebirth prevalence of severe congeni-
tal heart defects in the nine years before fortification
was slightly higher than the average birth prevalence
intheperiodafterfortification(averagerateratio1.64/
1000 (95% confidence interval 1.55 to 1.73) v 1.47/
1000 (1.37 to 1.58), table 2).
Time trends in birth prevalence of severe congenital heart
defects
The time trend analysis showed that there was no
change in the birth prevalence of severe congenital
heart defects in the period before fortification (time
RESEARCH
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afterthemandatoryfortificationofflourandpastawith
folic acid was accompanied by a 6.2% decrease per
yearinbirthprevalence(0.938,0.905to0.971)(figure,
table 2). The interaction between period (before/after
fortification) and calendar year was significant
(P<0.001), suggesting that the decreasing trend after
the flour fortification did not occur by chance.
Birth prevalence of conotruncal and non-conotruncal
defects
Infantswithconotruncalpathologyaccountedfor60%
of the study population (1248 infants), including 783
born in the period before fortification and 465 born
in the period after fortification. Over the 16 year
study period, the average birth prevalence of cono-
truncal defects was 0.94/1000 and the average birth
prevalence of non-conotruncal defects was 0.62/
1000. The annual birth prevalence of conotruncal
defects ranged from 0.70 to 1.14 cases per 1000 births
(interquartile range 0.85-1.05); and the annual birth
prevalence of non-conotruncal defects ranged from
0.34to0.85casesper1000births(0.54-0.71).Theaver-
agebirthprevalenceofbothconotruncalandnon-con-
otruncal defects was higher in the period before
fortification than in the period after fortification
(table 2).
Time trends in conotruncal and non-conotruncal defects
Time trend analysis for specific lesions showed trends
similartothoseobservedforallseverecongenitalheart
defects. For conotruncal defects we observed a slight
2.5%increaseperyearinbirthprevalenceintheperiod
before fortification (time trend rate ratio 1.025, 0.997
to1.053)thatwascurveddownwardintheperiodafter
fortification (0.948, 0.907 to 0.993), while for non-con-
otruncal defects there was no change in the period
before fortification (0.985, 0.953 to 1.018) followed
by a decrease in the period after fortification (0.912,
0.862 to 0.966) (table 2). The change in time trend
between the two periods was significant for both con-
otruncaldefects(P=0.004forinteraction)andnon-con-
otruncal defects (P=0.02).
Sensitivity analysis
When we excluded from the analyses the 83 infants
with congenital heart disease born in 2005 there was
minimalchangeintheresults.Specifically,theaverage
birth prevalence in the period after fortification
increased slightly from 1.47 to 1.54 cases/1000 births,
but remained below the birth prevalence in the period
before fortification (1.64/1000 births). Similarly, the
decreasing time trend in the period after fortification
decreased in magnitude, but remained significant
(0.954, 0.913 to 0.997), while the interaction term
also remained significant (P=0.03) (figure, bottom).
Removal of data from 2005 had a more important
impact on the lesion specific analyses, in which the
trends of both conotruncal and non-conotruncal
defects after fortification were no longer significant
(0.962, 0.909 to 1.018, and 0.943, 0.879 to 1.011,
respectively). The interaction term for conotruncal
defects remained significant (P=0.05), although lost its
significance for non-conotruncal defects (P=0.27).
DISCUSSION
Our population based study shows that fortification of
grain products with folic acid in Canada was followed
by a significant decrease in the birth prevalence of
severecongenitalheartdefects,supportingthehypoth-
esis that folic acid intake in the period around concep-
tion reduces the birth prevalence of severe congenital
heart defects. Specifically, we observed that the birth
prevalence did not change in the eight years before
fortification and decreased in the seven years after for-
tification. The change in time trend between the two
periods was significant both overall and for conotrun-
cal defects and non-conotruncal defects. There were
minimal changes in the estimates for the time trends
in the sensitivity analyses in which we excluded data
from 2005.
Our population based study adds to existing evi-
dence from other study designs
13-20 that, to date, was
inconclusive.
20 In 2007 a scientific statement from the
American Heart Association Council emphasised the
importance of corroborating the existing evidence
with evidence from population based studies.
20
Strengths and weaknesses
While the use of administrative databases gave our
study its main strength—allowing us to collect data at
a population level—it is also a limitation. Firstly,
administrative databases for medical claims are
known to be prone to misclassification and lack of
specificity.
33 To minimise misclassification errors, we
developedasystematicalgorithmthatcrossreferenced
diagnostic codes recorded in different administrative
databases.
23 Secondly, we identified affected infants
in the medical claims database according to the pre-
senceofrecordsofcongenitalheartdefectsinthe data-
base. Therefore, the longer a person was alive during
the years covered by the database, the higher the
chances of them being captured in the database. To
minimise the detection bias that would arise from
using different follow-up times, we chose a case
Table 2 |Changes in birth prevalence of severe, conotruncal and non-conotruncal, congenital
heart defects (CHD) before (1990-8) and after (1999-2005) mandatory fortification of flour
and pasta products with folic acid. Birth prevalence shown with 95% confidence intervals
Severe CHD Conotruncal Non-conotruncal
No of cases 2083* 1248 832
Birth prevalence/1000 births:
Before fortification 1.64 (1.55 to 1.73) 0.97 (0.91 to 1.04) 0.67 (0.61 to 0.72)
After fortification 1.47 (1.37 to 1.58) 0.90 (0.82 to 0.98) 0.57 (0.51 to 0.64)
Yearly change in birth prevalence:
Before fortification 0.8 (−1.3 to 3.0) 2.5 (−0.3 to 5.3) −1.5 (−4.7 to 1.8)
After fortification −6.2 (−9.5 to −2.9) −5.2 (−9.3 to −0.7) −8.8 (−13.8 to −3.4)
P value period-year
interaction
0.0005 0.004 0.02
*Total number of severe cases does not exactly match sum of conotruncal and non-conotruncal cases because
annual statistics on infant deaths and stillbirths provided by Quebec Death Registry were rounded to multiple of
five (see text).
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period of time—from birth to age 3—to be identified.
Thirdly, the annual and monthly statistics on infant
deaths and stillbirths due to severe congenital heart
defects were rounded to a multiple of five to preserve
patients’ anonymity. We addressed this limitation by
combining the information from the rounded statistics
by year and by month to obtain more accurate
monthly estimates. More importantly, the rounding is
not likely to change the annual trends. Indeed, the
rounded trends showed a decrease in infant deaths
due to severe congenital heart defects, which is consis-
tent with the continuous advancements in surgical
repairs that are likely to increase the survival of new-
borns with severe congenital heart defects.
34 Fourthly,
stillbirthsandinfantdeathsinthosewithsevereconge-
nital heart defects were identified according to the
diagnostic code recorded on the death certificate as
themaincauseofdeath.Itisunlikelythatmanyinfants
with severe congenital heart defects have died from
other problems. Fifthly, using administrative data we
could not measure directly the changes over time in
other risk factors for severe congenital heart defects,
which might have confounded the observed temporal
changes in birth prevalence. However, we succeeded
in finding indirect information on most risk factors for
severe congenital heart defects that are currently
known
20 (see below). Finally, in the absence of any
data on the timeline of the implementation of the new
folatepolicyinCanada,wehadtorelyonindirectdata
from the US to establish a lag time between the
announcement of the policy and its implementation.
Although the cut-off point between the two periods
might have been misclassified by several months, this
would probably bias the post-fortification trend
towards the null and reduce our ability to detect an
interaction, thus resulting in more conservative esti-
mates.
Notwithstanding these limitations, our birth preva-
lence estimates (1.08 to 1.81/1000) are consistent with
estimates fromother studies(1.5/1000 live births from
the New England Regional Infant Cardiac Program
35
and 1.71/1000 in the Atlanta metropolitan registry
36),
making us confident that our approach has indeed
maximised the accuracy and completeness of the
data. Given that this is the only population based
study to investigate the association between folic acid
and severe congenital heart defects and the only time
series analysis of this research question, we cannot
compare our results directly with results from other
studies. The strongest evidence to date for the associa-
tion between folic acid and congenital heart defects
comes from a randomised clinical trial
3738 in which
the presence of severe congenital heart defects was a
secondary outcome. The trial was the first study to
reportanassociationbetweenfolicacidandcongenital
heartdefectsandshowedthatwomentakingmultivita-
mins with 0.8 mg of folic acid had a 58% reduction in
the birth prevalence of congenital heart defects (rate
ratio 0.42, 0.19 to 0.98) and a 71% reduction in the
birth prevalence of conotruncal defects (0.29, 0.09 to
0.97).
3738 Perhaps the most likely explanation for why
theeffectdetectedinthattrialismuchstrongerthanthe
one we detected is that the dose of folic acid in multi-
vitamin supplements is significantly higher than the
target dose with fortification. Also, that trial was per-
formed in Hungary, and, because of possible differ-
ences in dietary folic intake at baseline, their results
might not be generalisable. Additional evidence from
several case-control studies
39-41 and some studies on
pregnant women taking drugs that are folic acid
antagonists
4243 is contradictory, probably because of
selection bias, recall bias,
4445 or misclassifications in
quantifying the total folic acid intake by the pregnant
women.
Biological mechanisms
Folic acid might have a role in the migration of the
cardiac neural crest cells that contribute to the forma-
tion of the truncus arteriosus and its division into the
aorta and pulmonary artery,
3031 thus probably affect-
ing the conotruncal defects in particular. The precise
role of folate supplementation on cardiac morphogen-
esis,however,remainsunclear,
3031 soit isimportant to
corroboratethishypothesiswithevidencefromclinical
and population based studies. To date, the hypothesis
is supported by the Hungarian randomised trial
3738
and several case-control studies,
3940 but not by other
case-control studies
41 nor by our population based
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Time trends in birth prevalence of severe congenital heart disease before and after 1 January
1999 cut off (see methods) representing introduction of mandatory fortification of flour and
pasta products with folic acid (vertical grey bars), including (top) and excluding (bottom,
sensitivity analysis) year 2005. Time trends estimated in each period by Poisson regression
with calendar time as independent variable
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followedbyareductioninthebirthprevalenceofboth
conotruncalandnon-conotruncaldefects,althoughthe
change in trend for non-conotruncal defects became
non-significantinthesensitivityanalysesthatexcluded
data from 2005. The subgroup with non-conotruncal
defectsinourstudy,however,wassmallerthantheone
with conotruncal defects, so when we deleted these
data in the sensitivity analyses the analysis might
have simply become too underpowered to detect an
effect. Consequently, we believe that there is not
enough evidence to rule out a possible effect in non-
conotruncal defects.
An average 6.2% reduction per year (4.6% in the
sensitivity analysis without data from 2005) in the
birth prevalence of severe congenital heart defects
observed in this study might seem modest. However,
giventhatseverecongenitalheartdefectsrequirecom-
plex surgical interventions in infancy and are asso-
ciated with high infant mortality rates,
46 even a small
reduction in the overall risk will significantly reduce
the costs associated with the medical care of these
patients and the psychological burden on patients
and their families. We might have underestimated the
true impact of folic acid on the birth prevalence of
severe congenital heart defects. Specifically, any mis-
classification of the cut-off point that separates the per-
iod before fortification from the period after
fortification is likely to bias towards the null the esti-
mate in the period after fortification. Furthermore, by
conductingapopulationbasedstudy,theeffectisaver-
agedacrosswomenwhodoanddonotbenefitfromthe
fortificationmeasure.Indeed,womentakingmultivita-
min supplementation are exposed to a high dose of
folic acid (0.4 to >1.0 mg/day) and might not benefit
fromthe folic acidfortificationmeasure, whichis setat
alowerlevel.
5Similarly,womenwithalowdailyintake
of bread and pasta might not benefit from dietary for-
tification.
Finally, our effect might be underestimated because
other factors that are known to increase the birth pre-
valence of congenital heart defects (such as maternal
obesity,
4748 pre-gestational diabetes,
4950 older mater-
nal age,
51 infants conceived with assisted reproductive
technologies,
52 medication such as antidepressant or
angiotensin converting enzyme inhibitors,
5354 mater-
nal transmission in women with congenital heart
defects
5556) have also increased over the study period.
Indeed, Canadian reports show that maternal
obesity,
57 diabetes among women,
58 maternal age,
59
and antidepressant use
60 and the number of pregnan-
cies in women with congenital heart defects
61 (who
have a 10-fold higher transmission risk than women
in the general population
5556) have increased in Que-
bec over the study period. Although no data on thera-
peutic abortions related to congenital heart defects
were available in Quebec, indirect data from the US
shows that prenatal screening for severe birth defects
(heart and other) has increased from 70% in the late
1980s to 93% in the late 1990s, while the percentage
of elective terminations among those screened has
decreasedfrom51%to44%.
62Ifthesetrendsweresimi-
lar in Quebec, then the birth prevalence would also be
expected to increase. Given that abortion rates are
usually culturally sensitive,
63 the US trends might not
applytoQuebec.Still,evenifweassumethattherapeu-
tic abortions rates have increased in Quebec, the
increase would probably have been gradual from one
yeartoanotherandwouldnotexplainthesuddendrop
in birth prevalence observed in our data immediately
after 1998.
Despite the limited descriptive data available to us
on concurrent secular trends in other risk factors, we
believe that our results are probably not caused by
chance because the timing of the observed effect coin-
cidesexactlywiththetimingofthefortification;thereis
biological plausibility for this association as shown in
animal studies
3031; and, with the exception of natural
andelectiveabortions(onwhichwehavenodatafrom
Quebec), all other factors that are known to increase
the birthprevalenceofseverecongenitalheartdefects,
such as older maternal age, more pregnancies in
women with congenital heart defects, maternal medi-
cation use, or obesity, have gradually increased over
the study period in Quebec
57-60 and, thus, cannot
explain the results.
Future population based studies could give more
accurate estimates if carried out in areas where data
on natural and elective abortions and their outcomes
are routinely collected, allowing the modelling of the
incidence of severe congenital heart defects, rather
than birth prevalence, as the dependent variable.
Furthermore, future population based studies with a
longer observation time could determine whether the
rates stabilise and a saturation point is achieved.
Finally, the optimal level of folic acid intake required
toachieveareductioninthebirthprevalenceofsevere
congenital heart defects remains unclear, as does the
dose-effect relation between the folic acid intake and
the birthprevalenceofseverecongenitalheartdefects.
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but inconclusive
Evidence from population based studies is lacking
WHAT THIS STUDY ADDS
The birth prevalence of severe congenital heart defects in Quebec, Canada, decreased after
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conception has a preventive effect on congenital heart defects
RESEARCH
page 6 of 8 BMJ | ONLINE FIRST | bmj.comFunding: AJM was funded by the Heart and Stroke Foundation of Canada.
ASM is funded by the Fonds de Recherche en Santé du Québec (FRSQ).
LPisaseniorinvestigatorfundedbytheFRSQandJamesMcGillprofessor
of Medicine. The study was funded in part by the Heart and Stroke
foundation of Canada and by the FRSQ.
Competing interests: None declared.
Ethical approval: This study was approved by Quebec Commission for
Access to Information, the McGill University Health Center ethics board,
and the Quebec Statistics Institute. The study is based on administrative
databases and subjects were not identifiable to the authors.
1 Rieder MJ. Prevention of neural tube defects with periconceptional
folic acid. Clin Perinatol 1994;21:483-503.
2 Pitkin RM. Folate and neural tube defects. Am J Clin Nutr
2007;85:285-8S.
3 De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, et al.
Reduction in neural-tube defects after folic acid fortification in
Canada. NE n g lJM e d2007;357:135-42.
4 Recommendations on the use of folic acid for the prevention of
neural tube defects. JS O G C1993;(suppl):41-6.
5 Bureau of Food Regulatory, International and Interagency Affairs,
HealthC.Regulatoryimpactanalysisstatement.CanadaGazettePart
II 1998;132(24):3029-33.
6 Food and Drug Administration. Food Standards. Amendment of
standards of identity for enriched grain products to require addition
of folic acid. Federal Register 1996;61:8781-96.
7 Ray JG. Folic acid food fortification in Canada. Nutr Rev
2004;62:S35-9.
8 Dietrich M, Brown CJ, Block G. The effect of folate fortification of
cereal-grain products on blood folate status, dietary folate intake,
anddietaryfolatesources among adultnon-supplementusersin the
United States. JA mC o l lN u t r2005;24:266-74.
9 Liu S, Longerich L, O’Connor K. Evaluation of food fortification with
folic acid for the primary prevention of neural tube defects: executive
summary 1997-2003. Public Health Agency of Canada,
2003. www.phac-aspc.gc.ca//publicat/faaf/pdf/folic_acid_e.pdf.
10 Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The
effect of folic acid fortification on plasma folate and total
homocysteine concentrations. NE n g lJM e d1999;340:1449-54.
11 Mills JL, Signore C. Neural tube defect rates before and after food
fortification with acid. Birth Defects Res A Clin Mol Teratol
2004;70:844-5.
12 Williams LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS, Hobbs CA,
et al. Prevalence of spina bifida and anencephaly during the
transition to mandatory folic acid fortification in the United States.
Teratology 2002;66:33-9.
1 3 A c u n aJ ,Y o o nP ,E r i c k s o nD .The prevention of neural tube defects
with folic acid. Atlanta, GA: Centers for Disease Control and
Prevention, 1999.
14 Health Canada. Congenital anomalies in Canada: a perinatal health
report. Ottawa:Minister of Public Works andGovernmentalServices,
2002.
15 Botto LD, Mulinare J, Erickson JD. Do multivitamin or folic acid
supplements reduce the risk for congenital heart defects? Evidence
and gaps. Am J Med Genet A 2003;121:95-101.
16 BottoLD,OlneyRS,EricksonJD.Vitaminsupplementsandtheriskfor
congenital anomalies other than neural tube defects. Am J Med
Genet C Semin Med Genet 2004;125:12-21.
17 Huhta JC, Hernandez-Robles JA. Homocysteine, folate, and
congenital heart defects. Fetal Pediatr Pathol 2005;24:71-9.
18 Bailey LB,Berry RJ. Folic acid supplementationand the occurrence of
congenital heart defects, orofacial clefts, multiple births, and
miscarriage. Am J Clin Nutr 2005;81:1213-7S.
19 Huhta JC, Linask K, Bailey L. Recent advances in the prevention of
congenital heart disease. Curr Opin Pediatr 2006;18:484-9.
20 Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, et al.
Noninherited risk factors and congenital cardiovascular defects:
current knowledge: a scientific statement from the American Heart
Association Council on Cardiovascular Disease in the Young:
endorsed by the American Academy of Pediatrics. Circulation
2007;115:2995-3014.
21 Minister of Public Works and Government Services. Congenital
anomalies in Canada—a perinatal health report, 2002. Ottawa:
Health Canada, 2002:15-9.
22 Blomberg M, Selbing A, Kallen B. Congenital malformations in the
southeast of Sweden—a registry study with validation. Acta Paediatr
2000;89:1238-43.
23 Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital
heart disease in the general population: changing prevalence and
age distribution. Circulation 2007;115:163-72.
24 Duchesne L. La situation demographique au Quebec: Bilan 2006.
Quebec: Institut de la Statistique du Quebec, 2006:69.
25 Canada S. CANSIM table 053-0001. Vital statistics, births, deaths
and marriages, quarterly. Ottawa: Statistics Canada, 2007.
26 Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart
defects in relation to maternal mulitivitamin use. Am J Epidemiol
2000;151:878-84.
27 de Jong-Van den Berg LT, Hernandez-Diaz S, Werler MM, Louik C,
Mitchell AA. Trends and predictors of folic acid awareness and
periconceptional use in pregnant women. Am J Obstet Gynecol
2005;192:121-8.
28 TamLE,McDonaldSD,WenSW,SmithGN,WindrimRC,WalkerMC.A
survey of preconceptional folic acid use in a group of Canadian
women. J Obstet Gynaecol Can 2005;27:232-6.
29 Blackburn S. Maternal, fetal and neonatal physiology: a clinical
perspective. 3rd ed. Edinburgh: Elsevier Saunders, 2007.
30 Tang LS, Wlodarczyk BJ, Santillano DR, Miranda RC, Finnell RH.
Developmental consequences of abnormal folate transport during
murine heart morphogenesis. Birth Defects Res A Clin Mol Teratol
2004;70:449-58.
31 Van Beynum IM, Kapusta L, den Heijer M, Vermeulen SH,
Kouwenberg M, Daniels O, et al. Maternal MTHFR 677C>T is a risk
factor for congenital heart defects: effect modification by
periconceptional folate supplementation. Eur Heart J
2006;27:981-7.
32 Naissances selon la duréed el ag r o s s e s s ee tl ep o i d sàla naissance,
Québec, 1975-2005. Quebec: Institut de la Statistique du Québec,
2007.
33 Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH,
Mark DB. Discordance of databases designed for claims payment
versus clinical information systems. Implications for outcomes
research. A n nI n t e r nM e d1993;119:844-50.
3 4 B o n e v aR S ,B o t t oL D ,M o o r eC A ,Y a n gQ ,C o r r e aA ,E r i c k s o nJ D .
Mortality associated with congenital heart defects in the United
States: trends and racial disparities, 1979-1997. Circulation
2001;103:2376-81.
35 Talner CN. Report of the New England Regional Infant Cardiac
Program, by Donald C. Fyler, MD, Pediatrics,
1980;65(suppl):375-461. Pediatrics 1998;102:258-9.
36 Botto LD, Correa A, Erickson JD. Racial andtemporal variations in the
prevalence of heart defects. Pediatrics 2001;107:E32.
37 Czeizel AE, Dobo M, Vargha P. Hungarian cohort-controlled trial of
periconceptional multivitamin supplementation shows a reduction
in certain congenital abnormalities. Birth Defects Res A Clin Mol
Teratol 2004;70:853-61.
38 CzeizelAE,MerhalaZ.Breadfortificationwithfolicacid,vitaminB12,
and vitamin B6 in Hungary. Lancet 1998;352:1225.
39 Scanlon KS, Ferencz C, Loffredo CA, Wilson PD, Correa-Villasenor A,
Khoury MJ, et al. Preconceptional folate intake and malformations of
the cardiac outflow tract. Baltimore-Washington Infant Study Group.
Epidemiology 1998;9:95-8.
40 Shaw GM, O’Malley CD, Wasserman CR, Tolarova MM, Lammer EJ.
Maternal periconceptional use of multivitamins and reduced risk for
conotruncalheartdefectsandlimbdeficienciesamongoffspring.Am
JM e dG e n e t1995;59:536-45.
41 Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin
supplementation and risk of birth defects. Am J Epidemiol
1999;150:675-82.
42 Czeizel AE, Rockenbauer M, Sorensen HT, Olsen J. The teratogenic
risk of trimethoprim-sulfonamides: a population based case-control
study. Reprod Toxicol 2001;15:637-46.
43 Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid
antagonists during pregnancy and the risk of birth defects. NE n g lJ
Med 2000;343:1608-14.
44 Bakker MK, de Walle HE, Dequito A, van den Berg PB, de Jong-van
denBergLT.Selectionofcontrolsincase-controlstudiesonmaternal
medication use and risk of birth defects. Birth Defects Res A Clin Mol
Teratol 2007;79:652-6.
4 5 W a c h o l d e rS .D e s i g ni s s u e si nc a s e - c o n t r o ls t u d i e s .Stat Methods
Med Res 1995;4:293-309.
46 Wen SW, Liu S, Joseph KS, Rouleau J, Allen A. Patterns of infant
mortality caused by major congenital anomalies. Teratology
2000;61:342-6.
47 Waller DK, Mills JL, Simpson JL, Cunningham GC, Conley MR,
Lassman MR, et al. Are obese women at higher risk for producing
malformed offspring? Am J Obstet Gynecol 1994;170:541-8.
48 Watkins ML, Botto LD. Maternal prepregnancy weight and congenital
heart defects in offspring. Epidemiology 2001;12:439-46.
49 Becerra JE, Khoury MJ, Cordero JF, Erickson JD. Diabetes mellitus
during pregnancy and the risks for specific birth defects: a
population-based case-control study. Pediatrics 1990;85:1-9.
50 AdamsMM,MulinareJ,DooleyK.Riskfactorsforconotruncalcardiac
defects in Atlanta. JA mC o l lC a r d i o l1989;14:432-42.
51 Reefhuis J, Honein MA. Maternal age and non-chromosomal birth
defects, Atlanta—1968-2000: teenager or thirty-something, who is
at risk? Birth Defects Res A Clin Mol Teratol 2004;70:572-9.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 7 of 852 Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth
defects after intracytoplasmic sperm injection and in vitro
fertilization. NE n g lJM e d2002;346:725-30.
53 Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S,
Gideon PS, et al. Major congenital malformations after first-trimester
exposure to ACE inhibitors. NE n g lJM e d2006;354:2443-51.
54 Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First
trimesterexposuretoparoxetineandriskofcardiacmalformationsin
infants: the importance of dosage. Birth Defects Res B Dev Reprod
Toxicol 2007;80:18-27.
5 5 B u r nJ ,B r e n n a nP ,L i t t l eJ ,H o l l o w a yS ,C o f f e yR ,S o m e r v i l l eJ ,e ta l .
Recurrence risks in offspring of adults with major heart defects:
results from first cohort of British collaborative study. Lancet
1998;351:311-6.
56 NoraJJ,NoraAH.Maternaltransmissionofcongenitalheartdiseases:
new recurrence risk figures and the questions of cytoplasmic
inheritance and vulnerability to teratogens. Am J Cardiol
1987;59:459-63.
57 Mongeau L, Audet N, Aubin J, Baraldi R. L’exces de poids dans la
population Quebecoise de 1987 a 2003. Quebec: Institute de la
Statistique du Quebec, 2005.
58 Portrait social du Quebec, donnees et analyses. Quebec: Institut de
la Statistique du Quebec, 2001.
59 Girard C. Le bilan demographique du Quebec. Quebec: Institut de la
Statistique du Quebec, 2007.
60 Ramos E, Oraichi D, Rey E, Blais L, Berard A. Prevalence and
predictors of antidepressant use in a cohort of pregnant women.
BJOG 2007;114:1055-64.
61 Bottega NA ZS, Ionescu-Ittu R, Therrien J, Martucci G, Pilote L,
Marelli AJ. Rising numbers of pregnancies and offspring in women
with congenital heart disease:a population-based study. Circulation
2008;118(18, suppl 2):S929.
62 Peller AJ, Westgate MN, Holmes LB. Trends in congenital
malformations,1974-1999: effect of prenatal diagnosisand elective
termination. Obstet Gynecol 2004;104:957-64.
63 Garne E, Loane M, Dolk H, De Vigan C, Scarano G, Tucker D, et al.
Prenatal diagnosis of severe structural congenital malformations in
Europe. Ultrasound Obstet Gynecol 2005;25:6-11.
Accepted: 28 January 2009
RESEARCH
page 8 of 8 BMJ | ONLINE FIRST | bmj.com